ViaCell to Present at the 2007 UBS Global Life                         Sciences Conference    CAMBRIDGE, Mass.--Sept. 18, 2007--ViaCell, Inc. (NASDAQ: VIAC) today announced that Marc D. Beer, President and Chief Executive Officer of ViaCell, will present an update on its business activities and product pipeline at the 2007 UBS Global Life Sciences Conference on Monday, September 24, 2007 at 12:00 p.m. at the Grand Hyatt Hotel in New York, NY. A live audio webcast of the presentation will be available on the Investor Information section of the ViaCell website at http://www.viacellinc.com/. A replay of the presentation will be available for approximately three months after the webcast.    About ViaCell    ViaCell, Inc. is a biotechnology company dedicated to enabling the widespread application of human cells as medicine. The Company markets ViaCord(R), a product offering through which families can preserve their baby's umbilical cord blood at the time of birth for possible future medical use in treating over 40 diseases including certain blood cancers and genetic diseases. The Company is also working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte(SM), a product candidate being studied for its potential to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell also conducts research and development primarily to investigate other potential therapeutic uses of umbilical cord blood-derived stem cells and on technology for expanding populations of these cells. ViaCell's pipeline is focused in the areas of cancer, cardiac disease, and diabetes. For more information about ViaCell, visit our website at http://www.viacellinc.com/.        ViaCell(R) and ViaCord(R) are registered trademarks and            ViaCyte(SM) is a service mark of ViaCell, Inc.    CONTACT: ViaCell, Inc.             Justine E. Koenigsberg, 617-914-3494             Senior Director, Corporate Communications